{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"145"}]}],"title":"Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"184"}]}],"title":"Any grade"}],"denoms":[{"counts":[{"groupId":"OG000","value":"452"},{"groupId":"OG001","value":"453"}],"units":"Participants"}],"description":"The Safety and Tolerability of nivolumab and ipilimumab was measured by the incidence of serious adverse events","groups":[{"description":"Nivolumab 3 mg/kg IV q2 wks and Ipilimumab placebo IV q3 wks for 4 doses then q12 wks starting at Wk 24","id":"OG000","title":"Nivolumab 3 mg/kg"},{"description":"Ipilimumab 10 mg/kg IV q3 wks for 4 doses then q12 wks starting at Wk 24 and Nivolumab placebo IV q2 wks","id":"OG001","title":"Ipilimumab 10 mg/kg"}],"paramType":"NUMBER","populationDescription":"all treated participants","reportingStatus":"POSTED","timeFrame":"reported between the first dose and 30 days after last dose of study therapy","title":"The Safety and Tolerability of Nivolumab and Ipilimumab Measured by the Incidence of Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}